<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://embryology.med.unsw.edu.au/embryology/index.php?action=history&amp;feed=atom&amp;title=Talk%3A2023_Project_6</id>
	<title>Talk:2023 Project 6 - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://embryology.med.unsw.edu.au/embryology/index.php?action=history&amp;feed=atom&amp;title=Talk%3A2023_Project_6"/>
	<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2023_Project_6&amp;action=history"/>
	<updated>2026-11-22T05:08:20Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.39.10</generator>
	<entry>
		<id>https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2023_Project_6&amp;diff=421347&amp;oldid=prev</id>
		<title>Z8600021: Created page with &quot;==References==  1.	Tang, Y., Durand, S., Dalle, S. &amp; Caramel, J. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment. Canc...&quot;</title>
		<link rel="alternate" type="text/html" href="https://embryology.med.unsw.edu.au/embryology/index.php?title=Talk:2023_Project_6&amp;diff=421347&amp;oldid=prev"/>
		<updated>2023-08-24T15:58:11Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;==References==  1.	Tang, Y., Durand, S., Dalle, S. &amp;amp; Caramel, J. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment. Canc...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==References==&lt;br /&gt;
&lt;br /&gt;
1.	Tang, Y., Durand, S., Dalle, S. &amp;amp; Caramel, J. EMT-Inducing Transcription Factors, Drivers of Melanoma Phenotype Switching, and Resistance to Treatment. Cancers (Basel). 12, 1–17 (2020). PMID: 32759677&lt;br /&gt;
&lt;br /&gt;
2.	Vandamme, N. &amp;amp; Berx, G. From neural crest cells to melanocytes: cellular plasticity during development and beyond. Cell. Mol. Life Sci. 76, 1919–1934 (2019). PMID: 30830237&lt;br /&gt;
&lt;br /&gt;
3.	Adameyko, I. et al. Schwann cell precursors from nerve innervation are a cellular origin of melanocytes in skin. Cell 139, 366–379 (2009). PMID: 19837037&lt;br /&gt;
&lt;br /&gt;
4.	Kaucka, M. et al. Nerve-associated Schwann cell precursors contribute extracutaneous melanocytes to the heart, inner ear, supraorbital locations and brain meninges. Cell. Mol. Life Sci. 78, 6033–6049 (2021). PMID: 34274976&lt;br /&gt;
&lt;br /&gt;
5.	Bonnamour, G., Soret, R. &amp;amp; Pilon, N. Dhh-expressing Schwann cell precursors contribute to skin and cochlear melanocytes, but not to vestibular melanocytes. Pigment Cell Melanoma Res. 34, 648–654 (2021). PMID: 33089656&lt;br /&gt;
&lt;br /&gt;
6.	Orlow, S. J. Melanosomes Are Specialized Members of the Lysosomal Lineage of Organelles. J. Invest. Dermatol. 105, 3–7 (1995). PMID: 7615972&lt;br /&gt;
&lt;br /&gt;
7.	Raposo, G. &amp;amp; Marks, M. S. Melanosomes — dark organelles enlighten endosomal membrane transport. Nat. Rev. Mol. Cell Biol. 2007 810 8, 786–797 (2007). PMID: 17878918&lt;br /&gt;
&lt;br /&gt;
8.	Cichorek, M., Wachulska, M., Stasiewicz, A. &amp;amp; Tymińska, A. Skin melanocytes: biology and development. Adv. Dermatology Allergol. Dermatologii i Alergol. 30, 30–41 (2013). PMID: 24278043 Review.&lt;br /&gt;
&lt;br /&gt;
9.	Arlo J Miller &amp;amp; Martin C Mihm Jr. Melanoma. N. Engl. J. Med. 355, 129–135 (2006). PMID: 16822996&lt;br /&gt;
&lt;br /&gt;
10.	Markovic, S. N. et al. Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis. Mayo Clin. Proc. 82, 364–380 (2007). PMID: 17352373&lt;br /&gt;
&lt;br /&gt;
11.	Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251–263 (2012). PMID: 22817889&lt;br /&gt;
&lt;br /&gt;
12.	Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27, 6199–6206 (2009).  PMID: 19917835&lt;br /&gt;
&lt;br /&gt;
13.	Pedri, D., Karras, P., Landeloos, E., Marine, J. C. &amp;amp; Rambow, F. Epithelial-to-mesenchymal-like transition events in melanoma. FEBS J. 289, 1352–1368 (2022). PMID: 33999497&lt;br /&gt;
&lt;br /&gt;
14.	Jaworek-Korjakowska, J. &amp;amp; Kleczek, P. ESkin: Study on the smartphone application for early detection of malignant melanoma. Wirel. Commun. Mob. Comput. 2018, (2018).&lt;br /&gt;
&lt;br /&gt;
15.	Borovansky, J., Mirejovsky, P. &amp;amp; Riley, P. A. Possible relationship between abnormal melanosome structure and cytotoxic phenomena in malignant melanoma. Neoplasma 38, 393–400 (1991). PMID: 1922572&lt;br /&gt;
&lt;br /&gt;
16.	Lazova, R. &amp;amp; Pawelek, J. M. Why do melanomas get so dark? Exp. Dermatol. 18, 934–938 (2009). PMID: 19645853&lt;br /&gt;
&lt;br /&gt;
17.	Dror, S. et al. Melanoma miRNA trafficking controls tumour primary niche formation. Nat. Cell Biol. 2016 189 18, 1006–1017 (2016). PMID: 27548915&lt;br /&gt;
&lt;br /&gt;
18.	Singh, S. K. et al. The silver locus product (Silv/gp100/Pmel17) as a new tool for the analysis of melanosome transfer in human melanocyte-keratinocyte co-culture. Exp. Dermatol. 17, 418–426 (2008). PMID: 18331332&lt;br /&gt;
&lt;br /&gt;
19.	Kawakami, Y. et al. The use of melanosomal proteins in the immunotherapy of melanoma. J. Immunother. 21, 237–246 (1998).  PMID: 9672845 Review.&lt;br /&gt;
&lt;br /&gt;
20.	Shain, A. H. &amp;amp; Bastian, B. C. From melanocytes to melanomas. Nat. Rev. Cancer 16, 345–358 (2016). PMID: 27125352 Review.&lt;br /&gt;
&lt;br /&gt;
21.	Shain, A. H. et al. The Genetic Evolution of Melanoma from Precursor Lesions. N. Engl. J. Med. 373, 1926–1936 (2015). PMID: 26559571&lt;br /&gt;
&lt;br /&gt;
22.	Rambow, F., Marine, J. C. &amp;amp; Goding, C. R. Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities. Genes Dev. 33, 1295–1318 (2019). PMID: 31575676&lt;br /&gt;
&lt;br /&gt;
23.	White, R. M. et al. DHODH modulates transcriptional elongation in the neural crest and melanoma. Nature 471, 518–522 (2011).&lt;br /&gt;
&lt;br /&gt;
24.	Diener, J. &amp;amp; Sommer, L. Reemergence of neural crest stem cell-like states in melanoma during disease progression and treatment. Stem Cells Transl. Med. 10, 522–533 (2021). PMID: 33258291&lt;br /&gt;
&lt;br /&gt;
25.	Huang, F., Santinon, F., Flores González, R. E. &amp;amp; del Rincón, S. V. Melanoma plasticity: promoter of metastasis and resistance to therapy. Front. Oncol. 11, (2021). PMID: 34604096 Review.&lt;br /&gt;
&lt;br /&gt;
26.	Rosenbaum, S. R. et al. SOX10 requirement for melanoma tumor growth is due, in part, to immune-mediated effects. Cell Rep. 37, 110085. (2021). PMID: 34879275&lt;br /&gt;
&lt;br /&gt;
27.	Abou-Hamad, J. et al. CEACAM1 is a direct SOX10 target and inhibits melanoma immune infiltration and stemness. iScience 25, 105524 (2022). PMID: 36437876&lt;br /&gt;
&lt;br /&gt;
28.	Boiko, A. D. et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466, 133–137 (2010). PMID: 20596026&lt;br /&gt;
&lt;br /&gt;
29.	Ngo, M. et al. Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts. Cell Rep. 16, 1701–1716 (2016). PMID: 27477289&lt;/div&gt;</summary>
		<author><name>Z8600021</name></author>
	</entry>
</feed>